Genetic Testing Market Analysis

Part
01
of eleven
Part
01

Competitors

5 of CancerIQ's competitors in the genetic testing market include Centogene, Gene by Gene, NeoGenomics, Ambry Genetics and Myriad. Each of these companies expansive operations in the U.S. and all are headquartered there, except Centogene whose headquarters are in Rostock, Germany.

Centogene


Myriad

  • Myriad was founded in 1991 . Since this was ten years before the human genome was sequenced, Myriad postulates that this makes them one of the pioneer companies in genomics.
  • Their product services includes molecular diagnostic tests for hereditary and urological cancer, autoimmune disorders, depression among other diseases. Myriad is accredited with discovering the following genes: BRCA1, BRCA2, p16, PTEN and ELAC2- various genes associated with many cancers.
  • A direct link to their website can be found here.
  • Myriad is an industry leader when it comes to prediction tools. EndoPredict is Myriad's cancer recurrence test that helps map out the possibility of recurrence within a 5-15 year time frame. It has also developed the Myriad My Risk Hereditary Cancer, a gene panel that identifies risks of breast, gastric, colorectal, pancreatic, ovarian, melanoma, endometrial and prostate cancers. riskScore, Myriad's revolutionary risk-predicting tool, is touted to predict a woman's risk in developing breast cancer within her remaining lifetime.
  • With presence in 128 countries and over 2,900 staff, Myriad prides itself as an international pioneer and leader in molecular diagnostics and precision medicine.


Gene by Gene


NeoGenomics


Ambry Genetics

  • Founded in 1999, Ambry Genetics was created with the sole mission to end disease through the provision of quality services in genetic testing. Their commitment to this led to the game-changing win against Myriad, a fellow genetics testing company, to abolish gene patenting that hindered research and slowed down medical testing.
  • Ambry's methodology for testing is optimized to continually detect variants in genetics to produce the most comprehensive and updated test results in the market. Through the industry's largest study of 20,000 cases, Ambry Genetics maintains that its methodology is unrivaled in its accuracy and conscientiousness.
  • A direct link to Ambry's website can be found here.
  • Ambry Genetics prides itself as a genetic testing company of firsts: first to offer exome services, first to revolutionize the industry by ending gene patenting and first to fund a platform dubbed AmbryShare that enables the sharing of their findings to further the war against disease.
  • Its 65,000 square foot Super Lab is also an industry first, a highly- automated facility designed to increase productivity and is touted to provide some of the industry's fastest turnaround times for accurate and specific results. It also provides DNA fingerprinting of samples for faster scalability and easier tracking.



Part
02
of eleven
Part
02

Competitive Landscape 3

What could be discovered on revenue, employees, and acquisitions is listed in detail here for Gene By Gene, NeoGenomics, and Ambry Genetics. One company did not list its revenue and only one of them has been acquired.

Gene By Gene

  • Gene by Gene's annual revenue is estimated to be around $20 million according to the only source found, although it may not be a reliable figure as most other reliable sources do not list their revenue or state that it is not disclosed. More information may on their revenue may be found at this paywalled site.
  • Once source states the company has between 51-200 employees, while another reliable source narrows the number down to 101-250.
  • Gene By Gene is independent, themselves acquiring Arpeggi Inc in 2013.

NeoGenomics

  • NeoGenomics annual revenue was listed at $102 million at one point in 2019.
  • The number of employees for NeoGenomics is listed between 501-1000.
  • The company is independent, themselves acquiring Genoptix Inc in 2018 in a $125 million deal, and an oncology division from Human Longevity for $37 million in 2020.

Ambry Genetics

Research Strategy

After thorough searching through databases, industry journals and websites, business profile websites, etc, Gene By Gene's annual revenue could only be found to be estimated from a potentially unreliable source, or hidden behind paywalled sites, if listed publicly at all. Other than that most of the requested data could be found, except an exact number of employees, where only a number range could be found for each company.
Part
03
of eleven
Part
03

Competitive Landscape 2

The estimated annual revenue and employee size for CRA Health are $7 million and 35 employees respectively. The FY 2018 revenue (United States operations only) and global employee size for Centogene are $19.022 million (€17.296 million) and 400 employees respectively. The global FY 2018 revenue and employee size for Myriad are $772.6 million and over 2,400 employees respectively.

CRA Health

  • The estimated annual revenue for CRA Health is $7 million.
  • The estimated employee size for the company is 35 employees.
  • CRA Health is a privately-held, independent company.

Centogene

Myriad

Part
04
of eleven
Part
04

Competitive Landscape 1

The estimated annual revenue and employee size for Progeny (subsidiary of Ambry Genetics) are $3.5 million and 18 employees respectively. The FY 2018 revenue and estimated employee size for NantHealth are $89.5 million and 543 employees respectively. The estimated annual revenue and employee size for CancerGene Connect/Ommdom (subsidiary of Invitae) are $180,766 and seven employees respectively.

Progeny

NantHealth

CancerGene Connect

  • CancerGene Connect (software developed by Ommdom) is a subsidiary of Invitae.
  • Invitae did not publish the revenue and employee size of CancerGene Connect/Ommdom in its 2018 annual report.
  • The estimated annual revenue for CancerGene Connect/Ommdom is $180,766.
  • The estimated employee size for the company is seven employees.
  • Ommdom was acquired by Invitae in June 2017.
  • Under the terms of the stock exchange agreement, Invitae purchased Ommdom’s “outstanding capital stock in exchange for approximately $6 million in Invitae common stock.”
  • According to the chief executive officer of Invitae Sean George, the acquisition allowed the company to “expand the tools we [Invitae] offer to clinicians using genetic information as part of patient care.”
  • Richard Burghardt, then chief executive officer of Ommdom stated that “joining Invitae will broaden the reach of our [Ommdom’s] technology, bringing its benefits to more clinicians and their patients.”
Part
05
of eleven
Part
05

Genetic Testing Market - Growth Rate

After an exhaustive search of market reports, industry publications, genetic testing companies, and general press, data on the growth rate of the genetic testing market in the United States does not appear to be in the public domain. The research team was, however, able to provide the future growth rate of the North American genetic testing market. The North American genetic testing market is expected to grow at a cumulative annual growth rate of 9.88% between 2019 and 2024.

North American Genetic Testing Growth Rate

  • Between 2019 and 2024, the North American genetic testing market is expected to experience a cumulative annual growth rate (CAGR) of 9.88%.
  • The factors driving the growth of the North American genetic testing market include "early disease detection and prevention, growing demand for personalized medicine, increasing application of genetic testing in oncology, and large demand for direct-to-customer genetic tests."
  • The biggest growth is expected in the predictive and pre-symptomatic testing that is used to detect gene mutation that could impair a person later in life.
  • The largest genetic testing type by revenue share is carrier testing, followed by newborn screening and diagnostic testing.
  • The North American genetic testing market is neither fragmented nor dominated by a few players. It can be, rather described as in-between being fragmented and dominated by a few players.
  • The United States genetic testing market was estimated at $6.34 billion for 2018, $7.94 billion for 2020, and $13.91 billion for 2025. [All calculations have been provided below]

Research Strategy

To determine the growth rate of the genetic testing industry in the United States, we commenced our research by searching for market reports on the subject matter. While the research team found many reports on the genetic testing market, we found that most of the available reports were focused on the global coverage of the industry (here, here, and here). The only report that was focused on the United States market was behind a paywall and did not provide any tangible free data that could be useful for this research.

We sought to triangulate an estimate for the current and future growth rate of the market by estimating the size of the industry in different years. We attempted to do this by combining the average cost of genetic tests and the total number of genetic tests done in the United States. In attempting this approach, the research team hit a stumbling block: the available and quoted data on the number of genetic tests (here and here) done in the United States typically include direct-to-consumer/at-home genetic tests, which means we could not use such figures.

However, during our research, we found some data points that we could combine to roughly estimate the current and future growth rate of the United States' genetic testing market based on some assumptions. However, on further inspection, since the market size of the United States genetic testing market size would be calculated using a global growth rate, the United States market automatically assumes the same growth rate as the calculations below show. As such, the research team could not provide the current or future growth rate of the United States genetic testing market.

The research team also broadened the scope of the research to North America because we reckoned that since the United States accounted for 91% of the North American generic testing market, it would be the major driver of all growth indices. The team was able to provide the future growth rate of the North American generic testing market.

Calculations

2018 United States Genetic Testing Market Size

According to Global Market Insights, the global genetic testing market was valued at $11.8 billion in 2018. The same report notes that North America represents 59% of the global market. Therefore, the North American genetic testing market in 2018 was:

59% of $11.8 billion = $6.962 billion

According to research by Global Market Insights, the United States accounted for 91% revenue share of the North American direct-to-consumer genetic testing industry. On the assumption that the revenue share of the direct-to-consumer genetic testing market is similar to the revenue share of the overall genetic testing market, we can assume that the United States enjoys a market share of 91% in the North American genetic testing market. Therefore, the size of the United States genetic testing market in 2018 is:

91% of $6.962 billion = $6.34 billion

2020 United States Genetic Testing Market Size

According to Global Market Insights, the global genetic testing market was valued at $11.8 billion in 2018 with an expected cumulative annual growth rate (CAGR) of 11.9% between 2019 and 2025. Based on the aforementioned data points, we can calculate the 2020 market size for the global genetic testing market using an online CAGR calculator and inputting the following variables:
  • Final value (2020 market size): Unknown
  • Initial value (2018 market size): $11.8 billion
  • Growth rate: 11.9% 
  • Number of periods (2018-2020): 2
The 2020 market size for the global genetic testing industry is $14.78 billion.

North America represents, 59% of the global genetic testing market. Therefore, the North America genetic testing market is valued at:
59% of $14.78 billion (as calculated above) = $8.72 billion

Based on our assumption above, the United States enjoys a market share of 91% in the North American genetic testing market. Therefore, the size of the United States genetic testing market in 2020 is:
91% of $8.72 billion = $7.94 billion

2025 United States Genetic Testing Market Size

According to Global Market Insights, the global genetic testing market was valued at $11.8 billion in 2018 with an expected cumulative annual growth rate (CAGR) of 11.9% between 2019 and 2025. Based on the aforementioned data points, we can calculate the 2020 market size for the global genetic testing market using an online CAGR calculator and inputting the following variables:
  • Final value (2025 market size): Unknown
The 2020 market size for the global genetic testing industry is $25.92 billion.

North America represents, 59% of the global genetic testing market. Therefore, the North America genetic testing market is valued at:
59% of $25.92 billion (as calculated above) = $15.29 billion

Based on our assumption above, the United States enjoys a market share of 91% in the North American genetic testing market. Therefore, the size of the United States genetic testing market in 2025 is:

91% of $15.29 billion = $13.91 billion

Growth Rate (2018-2020)

We can calculate the current growth rate between 2018 and 2020 for the United States genetic testing market using an online CAGR calculator and inputting the following variables:
  • Final value (2020 market size): $7.94 billion
  • Initial value (2018 market size): $6.34 billion
  • Number of periods (2018-2020): 2
  • Growth rate: Unknown variable
The estimated CAGR between 2018 and 2020 is 11.91%


Part
06
of eleven
Part
06

Genetic Testing Market Size

The United States genetic testing market is expected to reach $7.8 billion (calculations below) by the end of 2020. The primary drivers of the industry include a rise in the incidence of genetic diseases, advances in genetic testing, aging population, and increasing access to the procedure. Additional details on the United States genetic testing market have been detailed below, as well as all calculations and assumptions.

United States Genetic Testing Market

  • The United States genetic testing market has been roughly estimated to be valued at $7.8 billion by the end of 2020.
  • By the end of 2018, it was estimated that there would be "5,000 certified genetic counselors in the United States and Canada. "
  • Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in the United States marketed 74,448 genetic testing units (GTUs) as of March 2018. In 2017, more than 14 GTUs were entering the market per day.
  • According to McKinsey, the three major trends that will affect the market for genetic testing in the United States are:
    • "Data integration and analytics to realize the value of data have become increasingly important for the healthcare-delivery value chain."
    • "Payers are facing increasing pressure on costs and looking for new opportunities to control them."
    • "The US reimbursement landscape, which drives the profitability of most diagnostics players, is gradually evolving."
  • The primary drivers of the global genetic testing market include a rise in the incidence of genetic diseases, advances in genetic testing, aging population, and increasing access to the procedure.

Research Strategy

To determine the market size of the genetic testing industry in the United States, we commenced our research by searching for market reports on the subject matter. While the research team found many reports on the genetic testing market, we found that most of the available reports were focused on the global coverage of the industry (here, here, and here). The only report that was focused on the United States market were behind paywalls and did not provide any tangible free data that could be useful for this research.

We sought to triangulate an estimate for the market by combining the average cost of genetic tests and the total number of genetic tests done in the United States. In attempting this approach, the research team hit a stumbling block: the available and quoted data on the number of genetic tests (here and here) done in the United States typically include direct-to-consumer/at-home genetic tests, which means we could not use such figures.

However, during our research, we found some data points that we could combine to roughly estimate the size of the United States' genetic testing market based on a very plausible assumption. This triangulation has been detailed below.

Calculations

2020 Global Genetic Testing Market Size

According to Global Market Insights, the global genetic testing market was valued at $11.8 billion in 2018 with an expected cumulative annual growth rate (CAGR) of 11.9% between 2019 and 2025. Based on the aforementioned data points, we can calculate the 2020 market size for the global genetic testing market using an online CAGR calculator and inputting the following variables:
  • Final value (2020 market size): Unknown
  • Initial value (2018 market size): $11.8 billion
  • Growth rate: 11.9%
  • Number of periods (2018-2020): 2
The 2020 market size for the global genetic testing industry is $14.78 billion.

North America Genetic Testing Market

According to Global Market Insights, North America represents, 58% of the global genetic testing market. Therefore, the North America genetic testing market is valued at:
58% of $14.78 billion (as calculated above) = $8.57 billion

United States Genetic Testing Market

According to research by Global Market Insights, the United States accounted for 91% revenue share of the North American direct-to-consumer genetic testing industry. On the assumption that the revenue share of the direct-to-consumer genetic testing market is similar to the revenue share of the overall genetic testing market, we can assume that the United States enjoys a market share of 91% in the North American genetic testing market. Therefore, the size of the United States genetic testing market is:
91% of $8.57 billion = $7.8 billion




Part
07
of eleven
Part
07

Christopher Bun Biography

Christopher Bun has been the chief technology officer (CTO) of CancerIQ since 2015. He is an academic who is passionate about knowledge and enjoys reading research papers. His professional and personal biography has been provided below.

Professional

Career Track

Initiatives He Finds Important

  • Christopher finds important those initiatives that seek to show healthcare providers and patients that data and technology can help to solve real-world problems.
  • When asked about his role in CancerIQ, he responded by saying that he helps to make sure every bit of data and technology goes to its rightful place.

Quotes in Publications

  • In discussing CancerIQ's efforts in the healthcare industry, he said, "There are many problems that healthcare companies are trying to solve, but we make sure to remain focused on the problem at hand: People are dying of hereditary cancer that could have been prevented."
  • He also said, "Modern programming languages and frameworks allow us to design and deliver great user experiences, while our deployment tool-chain and container orchestration let us deploy new features many times a day," when talking about CancerIQ's approach to tackling hereditary cancer.
  • In responding to the things he has witnessed in his role as CancerIQ's CTO, he said, "We try to stay humble, but it does feel good when the praise from the IT administrators, users and patients continue to pour in."

Personal Life

Family Background

Any Hobbies

  • Christopher loves traveling evident from the various photos he shares on his social media pages of places he has visited including Madrid, Ibiza, Formentera, Naples, Capri, Positano, and Sorrento.

Passion

  • Christopher is an academic who is passionate about knowledge. He enjoys reading and analyzing research papers, an activity, he says, reminds him that there are people who are committed to constantly providing human knowledge.
  • He has listed more than 40 books he has read on Goodreads which include Freakonomics by Steven Levitt and Stephen Dubne, Mindfulness in Plain English written by Henepola Gunaratana, Incognito by David Eagleman, and Scientific Parallel Computing by Ridgway Scott, Babak Bagheri, and Terry Clark.
Part
08
of eleven
Part
08

Haibo Lu Biography

Haibo Lu, co-founder and VP of Product at CancerIQ, worked in a number of research and analytics positions prior to establishing CancerIQ. He's from Pennsylvania, currently lives in Chicago, is an avid runner, and enjoys playing guitar, to name a few of his interests. The entirety of our findings about Haibo's professional and personal biographies is provided below.

Professional Biography

1. Career Track

  • In 2008, Haibo graduated from Harvard University with a Bachelor's degree in Economics & Psychology.
  • In 2014, he earned his MBA degree from the Booth School of Business at the University of Chicago.
  • In his first job after college, he worked for AQR Capital Management "as a research analyst" in Greenwich, Connecticut. In that position, "he researched and developed investment strategies and trading algorithms in the futures and options space, with an emphasis on commodities, fixed income, equity indices, and currencies." He held that position from August 2008 to June 2010.
  • Thereafter, he embarked into the sports industry in becoming the "Head of Analytics for the Chinese Men's National Basketball Team" out of Shanghai and Beijing. In that role, he worked on advanced scouting and analytics regarding the 2012 Summer Olympics, 2011 FIBA Asia Championships, and the 2010 FIBA World Championships. He held that role from August 2010 to October 2011.
  • His next role was also in basketball, as he became the Shanghai Sharks' (team in the Chinese Basketball Association) Director of Basketball Operations. He held that role from August 2010 to July 2012.
  • His involvement with CancerIQ began in January 2013, while he was still an MBA student at the University of Chicago. At that time, he co-founded the company along with Feyi Olopade and Dr. Funmi Olopade. Currently, he's the VP of Product.

2. Important Initiatives

  • Data pilots are an initiative he finds important. In response to the question of what his "biggest fear [was] when . . . [he] co-founded CancerIQ", he replied, " I think my biggest fear was that we had a great idea and a great product, but that customers wouldn’t be willing to pay or would think that we were too expensive. The main way we overcame it was through data. We had a few pilots with our initial customers, and we were able to make an empiric case that CancerIQ delivers value."
  • In further regard to the importance he attaches to data initiatives, at CancerIQ he "[l]eads data and analytic development, systems creation, and implementation algorithms and processes."
  • Another initiative he considered important occurred when he was the Director of Basketball Operations for the Shanghai Sharks, as he "[r]esearched and built data systems and analysis engines to run statistical models to analyze player and team performance." He also "[l]ed the video team to capture, splice, and create training and scouting packages, as well as capture raw data for analytics."

3. Quotes in Publications

  • In discussing the impact of his company, Haibo stated the following: "At the end of the day, you’re doing something that really has a tangible effect. You can read statistics, and it’s kind of a big number. It’s knowing that our program and what we’re doing can help screen as many people as possible and help them detect cancers or prevent it all together. That has a much more kind of real feel."
  • In discussing the importance of intrinsic motivation for startup employees, Haibo stated the following: "I believe that we can help make things better. That belief is what’s going to guide you through some of the harder times. I think it’s really important to know that up front."
  • In response to Chicago being named by an "Innovation That Matters report" as "an Emerging Market for Civic Innovation" in 2015, Haibo said the following: "One great benefit of Chicago is that you can bring all these major actors together into a concentrated ecosystem that is more connected to the Heartland and less isolated than the coastal cities. Things that work in Chicago can spread to the rest of the country more easily."

Personal Biography

1. Family Background

2. Hobbies

3. Things He's Passionate About

4. TV, Movies, & Music

Part
09
of eleven
Part
09

Feyi Olopade Biography

Feyi Olopade previously worked at McKinsey & Company and Constant Capital. Her professional and personal biography are provided below.

Professional Life

Career Track

  • Since 2013, Feyi Olopade has been the CEO of Cancer IQ.
  • Olopade was a project manager of the Center for Clinical Cancer Genetics at the University of Chicago Hospitals from 2012 to 2013.
  • She was managing director at Wharton Social Venture Fund from 2010 to 2012.
  • From 2010 to 2012, she was an associate at Constant Capital.
  • In 2011, she was a summer associate at both McKinsey & Company and Actis.
  • In 2010, she was an investment officer at African Capital Alliance.
  • Olopade was an analyst at Credit Suisse from 2005 to 2008.

Initiatives She Finds Important

  • One reason Olopade started CancerIQ is the need for patient access to cutting edge clinical care. Her company tackles this by making it easier for physicians to predict and pre-empty cancer. Her company's software is being used for helping the Adventist Health Early All-Around Detection (AHEAD) initiative that focuses on genetic testing to identify cancer risk factors.
  • According to Olopade, "Adventist leadership is ensuring that genetic testing is not only a part of their innovation and specialty service line development strategy but a foundational part of their quality assurance, patient safety, and population health management initiatives."

Quotes

  • When answering to how her company is helping to make genetic services more practical in predicting and preventing cancer, she said: "it’s really through our software that we can automate the decisions that need to be made on the basis of that information, and make it relatively easy for the physician."
  • She also said, "the strategies that we use to educate patients on the benefits and the risks of genetic testing is really by using the channels that they really know and trust and believe in — the provider," when asked about the strategies being used to inform patients on the benefits of genetic services for cancer detection.
  • On how she raised $5.8 million for her startup, she said: "I don't know how many African American females you've seen out there raise a significant amount of capital, but it's not a lot."

Personal Life

Family Background

  • Olopade's mother is a renowned medical oncologist, Dr. Olufunmilayo Falusi Olopade. Among her most outstanding work is her research on the "genetics of breast cancer among women of African descent." She is also a co-founder of Cancer IQ.
  • Her father is Dr. Christopher Sola Olopade, a pulmonologist with expertise in asthma, chronic obstructive lung diseases, bronchiectasis, and eosinophilic lung diseases.
  • Her sister, Dayo Olopade, is author of The Bright Continent and worked on strategic media partnerships at Facebook. She currently runs YouTube content partnerships in Sub Saharan Africa.
  • She also has a younger brother, Tobi Olopade, who graduated from Harvard Business School and currently works at Amount as a senior manager.

Hobbies

Passions

Part
10
of eleven
Part
10

CancerIQ SWOT

CancerIQ has built a market-leading product platform that allows patients, providers, and healthcare executives to have genetic cancer evaluation at the point of care and thereby, design a tailored cancer prevention plan. As a key opportunity, the company can expand into other areas with genetic basis such as pediatric, prenatal, and cardiology genetics.

Strengths

  • The company operates a unique SaaS platform that allows healthcare providers to leverage the genetic information of individuals to predict, preempt, and avert cancer.
  • The company has witnessed rapid growth since its commercialization in 2015 and has managed to garner more than 30 clients within a short span of time. These include both private practices and larger healthcare systems, such as OSF HealthCare, Advocate Health Care, and Adventist Health System.
  • The company has been able to successfully raise capital in order to bolster its expansion plans. Within 3 years of commercialization, the company has managed to raise over $5 million in VC funding from investors like Michael Polsky, KGC Capital, and Eric Lefkofsky’s Lightbank.
  • In addendum, the company's platform has proved extremely successful and has helped screen more than 115,000 patients thus far. This corroborates the growing popularity of the platform among healthcare providers.
  • The company leverages predictive analytics and screening tools which allows it to churn out accurate screening results. In addition, the company's solutions are faster and cheaper for physicians to implement.
  • The company's platform is capable of fully integrating with EHRs, genetics laboratories, and specialty software vendors that help them "streamline workflow, guide clinician decision-making, and achieve cost savings."
  • In 2016, within one year of its commercialization, the company was nominated at the Chicago Innovation Awards and won the 'Up-and-Comer' award for its groundbreaking work in healthcare technology.

Weaknesses

  • As per the estimates from Zoominfo, the company's revenue has fallen or remained constant over the past year. The same has dropped from $13.6 million in Q1'19 to $11.8 million in Q2'19 and has remained constant over Q3'19. This signals weakness or cyclicity in its operations that can lead to operating cash flow problems.
  • The company currently lacks the competency to offer genetic testing solutions for critical diseases other than cancer, such as cardiovascular diseases. This limits the market expansion opportunity for CancerIQ and hence, is a current weakness for the company.
  • The company has a poor rating of 2.4/5 on the Glassdoor platform from its employees. Most of the reviews have highlighted glitches in the senior leadership of the company. Thus, low employee satisfaction is a potential weakness for CancerIQ.

Opportunities

Threats

  • The cancer genetic testing space is highly competitive and hence, CancerIQ faces the threat of new entrants with disruptive technologies. Some leading players operating in the industry and working upon developing new technologies include Exact Sciences, Genomic Health, Invitae, Natera, Veracyte, and Myriad Genetics among others.
  • While the company has thus far managed to tap the VC funding without many hurdles, any significant tightening in the financing market owing to the economic slowdown in the United States can hugely impact the company's ability to shore up addendum funds, thereby, threatening its expansion plans.
  • The genetic testing industry is highly regulated and is subject to regulations by multiple regulators such as the Clinical Laboratory Improvement Amendments (CLIA), FDA, Federal Trade Commission (FTC), etc.
  • Additionally, the promotion of genetic tests and services to consumers is restricted in several ways. Hence, any adverse regulatory action can again prove to be a threat to the expansion plans of the company.
Part
11
of eleven
Part
11

CancerIQ Overview

CancerIQ, Inc is headquartered in Chicago, Illinois and has 11-50 employees. The company's press coverage in the past 12 months includes the integration of the company's cancer risk assessment software with the systems of healthcare providers such as GeneMatters and Adventist Health. The press coverage also includes the recognition of the initiatives made by the company's CEO, Feyi Olopade Ayodele.

Overview

Press Scan

CancerIQ Inc's last 12-month press coverage includes the following significant events and announcements:

  • CancerIQ Inc's risk assessment software raising the number of patients identified as high cancer risk 2.5 times and increasing those eligible for Magnetic Resonance Imaging (MRI) surveillance in March 2019.
  • The partnership of CancerIQ Inc with AliveAndKickn and the National Comprehensive Cancer Network (NCCN) to provide screening and counseling services to Lynch Syndrome patients and equip healthcare providers with patient management skills respectively, in March 2019.
  • The integration of CancerIQ Inc's platform with Adventist Health's Cerner EHR system to help in identifying potential candidates for genetic testing in May 2019.
  • An interview with CancerIQ Inc's CEO, Feyi Olopade Ayodele, on the importance of prevention and early detection of cancer through genetic testing in May 2019.
  • CancerIQ Inc's partnership with GeneMatters to provide easy access to genetic counseling, identification of hereditary cancers, and prevention through integration of their software technologies in June 2019.
  • The featuring of CancerIQ's CEO and founder, Feyi Olopade Ayodele, in 5 Chicago female CEOs finding success in technology in August 2019.
  • The adoption of CancerIQ Inc's questionnaire in the cancer risk assessment by UnityPoint Health's combined use mHeath and telehealth in care management in August 2019.
  • The integration of CancerIQ Inc's genetics assessment software with OSF HealthCare's Epic EHR software for more efficient cancer screening in September 2019.
  • Being one of the recipients of Impact Engine's $25 million fund in November 2019.
  • The hiring of the experienced oncologist and genomics expert, Kelly Hall, into the commercial strategy and operations department, as vice president in December 2019.


Sources
Sources

From Part 06
From Part 09
From Part 11